Johnson & Johnson (JNJ) stock is in focus after FDA clearance of the MONARCH QUEST 3 bronchoscopy system, along with momentum in its Innovative Medicine segment despite ongoing STELARA biosimilar headwinds.

At a share price of $262.37, Johnson & Johnson has a 90 day share price return of 14.07% and a year to date share price return of 26.53%. The 1 year total shareholder return of 52.58% points to strong recent momentum building around products like MONARCH QUEST 3 and the growth in Innovative Medicine.

If the recent move in Johnson & Johnson has you looking at healthcare and medical technology more broadly, this can be a useful moment to scan for other AI driven healthcare opportunities using the 40 healthcare AI stocks.

Johnson & Johnson now has a sizeable, diversified healthcare business and a stock that has run hard on that story. The next step is to ask whether the current price still reflects a reasonable entry point.

Most Popular Narrative: 13.7% Overvalued

According to the most followed valuation narrative, Johnson & Johnson's fair value is set at $230.82, compared with the recent share price of $262.37. That gap is what drives the current overvaluation call.

AI-augmented MedTech (robotics, imaging analytics), premium device pricing plus subscriptions.

Curious what earnings profile could back this kind of valuation stretch. The narrative leans on rising revenue, firmer margins and a richer profit multiple over time. The full set of projections shows how those pieces are expected to fit together.

Result: Fair Value of $230.82 (OVERVALUED)

However, this Johnson & Johnson AI narrative can crack if regulators push back on AI generated evidence or if faster moving rivals capture key oncology and MedTech markets.

Another View on Johnson & Johnson's Valuation

The user generated AI narrative identifies Johnson & Johnson as 13.7% overvalued at $262.37 versus a fair value estimate of $230.82. Our DCF model presents a different perspective. It indicates the stock is trading about 28% below an estimated future cash flow value of $364.27.

This difference between the narrative fair value and the SWS DCF model raises a clear question: which set of assumptions about cash generation and AI driven execution appears more realistic for Johnson & Johnson over time?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment on Johnson & Johnson is mixed, with clear upside hopes and real concerns in the background. Review the data now and weigh both sides using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Johnson & Johnson?

If you want to build on what you have learned about Johnson & Johnson, use this moment to scan other opportunities that could sharpen your overall portfolio positioning.

• Target potential value opportunities by checking companies that look attractively priced on quality and fundamentals using the 53 high quality undervalued stocks.
• Strengthen your focus on resilience by reviewing companies highlighted in the 80 resilient stocks with low risk scores which may offer more stable risk profiles.
• Hunt for less crowded opportunities by scanning the screener containing 19 high quality undiscovered gems that combine strong fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.